Latest database descriptions

Describe the population pursuing SERETIDE Diskus 500 µg / 50 doses within the framework of treating OCPD, the methods for prescribing it and their actual conditions of use (observance in particular) as well as the clinical change in patients.

Evaluate the impact of the fixed-dose combinations on objective morbidity and on perceived morbidity of OCPD.

Validate a new satisfaction questionnaire for patients with regards to their treatment with Anti TNF in Crohn's disease at a severe and evolving stage

Describe the prophylactic treatment of phlebitis in patients suffering from multiple myeloma and receiving thalidomide or lenalidomide treatment:
- Describe the proportion of patients under prophylactic treatment for phlebitis;
- Define the importance of low-molecular-weight heparins (LMWH), vitamin K antagonists (VKA) and aspirin, as well as the arrangements for their use in preventing phlebitis.

Describe, over a period of 4 and then 8 months, the occurrence of thromboembolic and hemorrhagic events in patients with multiple myeloma who are under thalidomide or lenalidomide treatment, depending on the thromboprophylactic strategy set up upon inclusion

Primary objective: determine the incidence of clinical vertebral fractures and non-vertebral fragility fractures in patients treated with teriparatide for about 18 months and a post-treatment follow-up period of at least 18 months.
Secondary objectives: observance, treatment switching and cessation, clinical evolution, occurrence of back pain, direct costs linked to fractures.